Efavirenz-induced exfoliative dermatitis.
Individuals with a human immunodeficiency virus (HIV) infection are at higher risk of developing adverse drug reactions. Multiple drugs are usually prescribed to patients with HIV infection for preventing the replication of HIV and for the treatment of the associated opportunistic infections. We report here the first case of an HIV-1-infected patient who developed an exfoliative dermatitis induced by efavirenz, a non-nucleoside reverse transcriptase inhibitor. Physicians should be aware of the possible occurrence of efavirenz-induced skin eruptions from the start of antiviral treatment of HIV infection.
Department of Infectious Diseases, PLA Center for the Treatment of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jiu-Cong
JC
Zhang
Yong-Tao
YT
Sun
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D048588:Benzoxazines / Q000009:adverse effects* / Q000627:therapeutic use*; D003521:Cyclopropanes; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000473:pathology; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; C098320:efavirenz